I’m going to lead with the name because I think it deserves it. The study is called CYBORG.
Phantom Neuro received approval to begin its first-in-human Early Feasibility Study in Australia, evaluating the Phantom X system in up to 10 below-elbow amputee patients. The Phantom X is a minimally invasive muscle-machine interface that translates muscle signals into control of prosthetic limbs and robotic devices.
Current prosthetic control is, frankly, primitive for most patients. Surface electrodes pick up skin-level muscle signals, but they’re noisy, inconsistent, and limited in the number of gestures they can reliably decode. The Phantom X implants sensors directly into the muscle, which should give much cleaner signal resolution and more intuitive control.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
The company previously completed an 11-patient feasibility study assessing gesture accuracy, so there’s some early human experience with the system. But this CYBORG trial is the real milestone: a formal EFS evaluating safety, functionality, and usability in a controlled setting.
Phantom Neuro raised a $19 million Series A from Breakout Ventures back in April 2025, so they’ve been building toward this moment for about a year. The end goal is U.S. commercialization, but starting in Australia gives them a faster regulatory pathway to first-in-human data.
The broader implications are worth thinking about too. A reliable muscle-machine interface doesn’t stop at prosthetics. Exoskeletons, surgical robots, industrial applications. The platform is the product here, not any single device.
Ten patients. One study. And a name that sounds like it belongs in a movie, not a clinical trial registry. But if Phantom X delivers the signal clarity the company expects, the sci-fi name might end up being appropriate.
